Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses

Journal of Immunology

Volumn 172, Issue 3, 2004, Pages 1380-1390

  Dobrzanski, Mark J ^a   Reome, Joyce B ^a   Hollenbaugh, Joseph A ^a   Dutton, Richard W ^a  

^a TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOCYTE SURFACE MARKER; OVALBUMIN; PERFORIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

EID: 1642567230     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.3.1380     Document Type: Article

References (62)

1. Yee, C., J. A. Thompson, P. Roche, D. R. Bryd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg. 2000. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192:1637.
2. Dudley, M. E., J. R. Wunderlich, J. R. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Toplalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
3. Yee, C., J. A. Thompson, D. Bryd, S. R. Ridell, P. Roche, E. Celis, and P. D. Greenberg. 2002. Adoptive T cell therapy using antigen-specific CD8 T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99:16168.
4. Meidenbauer, N., J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen. 2003. Survival and tumor localization of adoptively transferred melan-A-specific T cells in melanoma patients. J. Immunol. 170:2161.
5. Yee, C., P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162:2227.
6. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677.
7. Dunbar, P. R., C. L. Smith, D. Chao, M. Salio, D. Shepherd, F. Mirza, M. Lipp, A. Lanzavecchia, F. Sallusto, A. Evans, et al. 2000. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. 165:6644.
8. Mandruzzato, S., E. Rossi, F. Bernardi, V. Tosello, B. Macino, G. Basso, V. Chiarion-Sileni, C. R. Rossi, C. Montesco and P. Zanovello. 2002. Large and dissimilar repertoires of melan-A/MART-1 specific CTL in metastatic lesions and blood of a melanoma patient. J. Immunol. 169:4017.
9. Yee, C., and P. Greenberg. 2002. Modulating T cell immunity to tumors: new strategies for monitoring T cell responses. Nat. Rev. Cancer 2:409.
10. Monsurro, V., D. Nagorsen, E. Wang, M. Provenzano, M. E. Dudley, S. A. Rosenberg, and F. M. Marincola. 2002. Functional heterogeneity of vaccine-induced CD8 T cells. J. Immunol. 168:5933.
11. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795.
12. Correa, M. R., A. C. Ochoa, P. Ghosh, H. Mizoguchi, L. Harvey, and D. L. Longo. 1997. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158:5292.
13. Speiser, D. E., M. J. Pittet, R. Dunbar, D. Rimoldi, D. Lienard, H. Robson Mcdonald, J. Cerundolo, and P. Romero. 1999. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med. 190:775.
14. Moser, J. M., J. Gibbs, P. E. Jensen, and A. E. Lukacher. 2002. CD94-NKG2A receptors regulate antiviral CD8 T cell responses. Nat. Immunol. 3:189.
15. Tham, E. L., P. Shrikant, and M. F. Mescher. 2002. Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response. J. Immunol. 168:1190.
16. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Salomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: preliminary report: N. Engl. J. Med. 319:1676.
17. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and IL-2. J. Natl. Cancer Inst. 86:1159.
18. Yee, C., M. J. Gilbert, S. R. Riddell, V. G. Brichard, A. Fefer, J. A. Thompson, T. Boon, and P. D. Greenberg. 1996. Isolation of tyrosinase-specific CD8 and CD4 T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol. 157:4079.
19. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. Sznol, S. L. Schwarz, P. J. Spiess, et al. 1999. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163:1690.
20. Rosenberg, S. A. 2001. Progress in human tumor immunology and immunotherapy. Nature 411:380.
21. Robbins, P. F., M. El-Gamil, Y. F. Li, G. Zeng, M. Dudley, and S. A. Rosenberg. 2002. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor infiltrating lymphocytes from a patient with melanoma. J. Immunol. 169:6036.
22. Hu, H., H. Winter, W. J. Urba, and B. A. Fox. 2000. Divergent roles for CD4 T cells in the priming and effector/memory phases of adoptive immunotherapy. J. Immunol. 165:4246.
23. Hess, S. D., N. K. Egilmez, N. Bailey, T. M. Anderson, E. Mathiowitz, S. H. Bernstein, and R. B. Bankert. 2003. Human CD4 T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J. Immunol. 170:400.
24. Hung, K., A. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll and H. Lavitsky. 1998. The central role of CD4 T cells in the antitumor immune response. J. Exp. Med. 12:2357.
25. Tatsumi, T., L. S. Kierstead, E. Ranierri, L. Gesualdo, F. P. Schena, J. H. Finke, R. M. Bukowski, J. Mueller-Berghaus, J. M. Kirkwood, W. W. Kwok, et al. 2002. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4 T cell responses against MAGE-6 in HLA-DRB1 0401 patients with renal cell carcinoma or melanoma. J. Exp. Med. 196:619.
26. Mumberg, D., P. A. Monarch, S. Wandderling, M. Philip, A. Y. Toledano, R. D. Schreiber, and H. Schreiber. 1999. CD4 T cells eliminate MHC class 11-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96:8633.
27. Croft, M., L. L. Carter, S. L. Swain, and R. W. Dutton. 1994. Generation of polarized antigen specific CD8 effector populations: reciprocal actions of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:1715.
28. Carter, L. L., and R. W. Dutton. 1996. Type 1 and type 2: a fundamental dichotomy for all T cell subsets. Curr. Opin. Immunol. 8:336.
29. Sad, S., R. Marcotte, and T. R. Mosmann. 1995. Cytokine induced differentiation of precursor mouse CD8 T cells into cytotoxic CD8 T cells secreting th1 or th2 cytokines. Immunity 2:271.
30. Vukmanovic-Stejic, M., B. Vyas, P. Gorak-Stolinska, A. Noble, and D. M. Kemeny. 2000. Human Tc1 and Tc2/Tc0 CD8 T cell clones display distinct cell surface and functional phenotypes. Blood 95:231.
31. Salgame, P., J. S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R. L. Modlin, and B. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279.
32. Maggi, E., M. G. Giudzi, R. Biagiotti, F. Annunziato, R. Manetti, M. P. Piccinni, P. Parronchi, S. Sampognaro, L. Giannarini, G. Zuccati, et al. 1994. Th2-like CD8 T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type I infection. J. Exp. Med. 180:489.
33. Maggi, E., R. Manetti, F. Annunziato, L. Cosmi, M. G. Giudizi, R. Biagiotti, G. Galli, G. Zuccati, and S. Romagnani. 1997. Functional characterization and modulation of cytokine production by CD8 T cells from human immunodcficiency virus-infected individuals. Blood 89:3672.
34. Dobrzanski, M. J., J. B. Reome, and R. W. Dutton. 2000. Type 1 and type 2 CD8 effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumors. J. Immunol. 164:916.
35. Hogquist, K. A., S. C. Jameson, W. R. Health, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonistic peptides induce positive selection. Cell 76:17.
36. Altman, J. D., P. H. Moss, P. R. Goulder, M. G. Barouch, J. I. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
37. + T cell subpopulations in established pulmonary metastases. J. Immunol. 162:6671.
38. Dutton, R. W., L. M. Bradley, and S. L. Swain. 1998. T cell memory. Annu. Rev. Immunol. 16:201.
39. Homey, B., A. Muller, and A. Zlotnik. 2002. Chemokines: agents for immunotherapy of cancer. Nat. Rev. Immunol. 2:175.
40. Dobrzanski, M. J., J. B. Reome, and R. W. Dutton. 2001. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. J. Immunol. 167:424.
41. Dobrzanski, M. J., J. B. Reome, and R. W. Dutton. 2001. Immunopotentiating role of IFN-γ in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98:70.
42. Winter, H., H. Hu, W. J. Urba, and B. A. Fox. 1999. Tumor regression after adoptive transfer of effector T cells is independent of perforin or fas ligand (APO1L/CD95L). J. Immunol. 163:4462.
43. Prevost-Blondel, A., M. Neuenhahn, M. Rawiel, and H. Pircher. 2000. Differential requirements of perforin and IFN-γ in CD8 T cell-mediated immune responses against B16-F10 melanoma cells expressing a viral antigen. Eur. J. Immunol. 30:2507.
44. Radoja, S., M. Saio, D. Schaer, M. Koneru, S. Vukmanovic, and A. B. Frey. 2001. CD8 tumor infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol. 167:5042.
45. Bose, A., Y. Inoue, K. E. Kokko, and F. G. Lakkis. 2003. Cutting edge: perforin down-regulates CD4 and CD8 T cell-mediated immune responses to a transplanted organ. J. Immunol. 170:1611.
46. Nishimura, T., K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahta, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, et al. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190:617.
47. Schuler, T., T. Kammertoens, S. Preiss, P. Debs, N. Noben-Trauth, and T. Blankenstein. 2001. Generation of tumor-associated CTL requires interleukin 4 from CD8 T cells. J. Exp. Med. 194:1767.
48. Kobayashi, M., H. Kobayashi, R. B. Pollard, and F. Suzuki. 1998. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastases of murine B16 melanoma. J. Immunol. 160:5869.
49. Sheu, B., R. Lin, H. Lien, H. Ho, S. Hsu, and S. Huang. 2001. Predominant Th2/Tc2 polarity of tumor infiltrating lymphocytes in human cervical cancer. J. Immunol. 167:2972.
50. Kacha, A. K., F. Fallarino, A. A. Markiewicz, and T. F. Gajewski. 2000. Cutting edge: spontaneous rejection of poorly immunogenic PI.HTR tumors by Stat6-deficient mice. J. Immunol. 165:6024.
51. Ostrand-Rosenberg, S., M. J. Grusby, and V. K. Clements. 2000. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165:6015.
52. Hu, H., W. J. Urba, and B. A. Fox. 1998. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell responses from a type 2 to a type 1 cytokine profile. J. Immunol. 161:3033.
53. Fallarino, F., and T. F. Gajewski. 1999. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J. Immunol. 163:4109.
54. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Auguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon-γ -dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95:7556.
55. Winter, H., H. M. Hu, C. H. Poehlein, E. Huntzicker, J. J. Osterholzer, J. Bashy, D. Lashley, B. Lowe, J. Yamada, G. Alvord, et al. 2003. Tumor-induced polarization of tumor vaccine-draining lymph node T cells to a type I cytokine profile predicts inherent strong immunogenicity of the tumor and correlates with therapeutic efficacy in adoptive transfer studies. Immunology 108:409.
56. Cope, A. P., R. S. Liblau, X. D. Yang, M. Congia, C. Laudanna, R. D. Schreiber, L. Probert, G. Kollias, and H. O. Mcdevitt. 1997. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signalling. J. Exp. Med. 185:1573.
57. Isomaki, P., M. Panesar, A. Annenkov, J. M. Clark, B. M. J. Foxwell, Y. Chemajovsky, and A. P. Cope. 2001. Prolonged exposure of T cells to TNF down-regulates TCR-ζ and expression of the TCR/CD3 complex at the cell surface. J. Immunol. 166:5495-5507.
58. Farrar, J. D., J. H. Katz, J. Windsor, G. Thrush, R. H. Scheuermann, J. W. Uhr, and N. E. Street. 1999. Cancer dormancy: a regulatory role for CD8 T cells and IFN-γ in establishing and maintaining the tumor dormant state. J. Immunol. 162:2842.
59. Beatty, G. L., and Y. Paterson. 2000. IFN-γ can promote tumor evasion of the immune system in vivo by down regulating cellular levels of an endogenous tumor antigen. J. Immunol. 165:5502.
60. Lukacher, A. E. 2002. IFN-γ suspends the killing license of anti-tumor CTLs. J. Clin. Invest. 110:1407.
61. Le Poole, I. C., A. I. Riker, M. E. Quevedo, L. S. Stennett, E. Wang, F. M. Marincola, W. M. Kast, J. K. Robinson, and B. J. Nickoloff. 2002. Interferon-γ reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am. J. Pathol. 160:521.
62. Malmberg, K., V. Levitsky, H. Norell, C. Teixeira de Matos, M. Carlsten, K. Schedvins, H. Rabbani, A. Moretta, K. Soderstrom, J. Levitskaya, et al. 2002. IFN-γ protects short term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 110:1515.